IMAB stock faces mixed ratings after a USD 20.60 million cash outflow
Published on 09/29/2026 at 15:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IMAB stock stood at USD 1.61 on September 14, 2026, while its 52-week high was USD 6.79 and the stock was down 60.00 percent year to date, according to a dated conference report. The clinical-stage biotech is now being assessed through a mix of analyst caution, pipeline execution and cash discipline.
Ratings remain sharply divided
MarketBeat reported on September 15, 2026, that Wall Street Zen upgraded I-Mab from strong sell to sell. The same report put the analyst consensus at Hold and the average target price at USD 9.00, with HC Wainwright maintaining a buy rating and the same target on August 20, 2026.
The contrast is material. The USD 9.00 consensus target stands 459.01 percent above the USD 1.61 share price cited on September 14, 2026, while the Hold consensus shows that the target does not translate into a uniform analyst view.
Cash flow tests the biotech case
Fundamentals Hub lists fiscal 2025 revenue of USD 632,000 and operating cash flow of minus USD 20.60 million. Operating cash flow therefore exceeded revenue in absolute terms by USD 19.97 million, a gap that keeps funding capacity central to the investment case.
MarketBeat also reported a quarterly loss of USD 0.16 per share and disclosed that Sean Wuxiong Cao sold 107,978 shares at an average USD 0.74 on September 9, 2026. The filing-linked transaction was described as covering tax withholding tied to vested equity awards.
Stock remains far below yearly high
Market capitalization was USD 186.2 million on September 15, 2026. The 52-week range was USD 1.46 to USD 6.79, placing the USD 1.61 reference price USD 5.18, or 76.29 percent, below the yearly high.
Investing.com reported on September 14, 2026, that NovaBridge presented a strategy centered on sourcing later-stage Asian drug assets and advancing them through a US clinical development platform. For investors, the central tension is visible in the numbers: a USD 9.00 target contrasts with a USD 20.60 million fiscal 2025 operating cash outflow.
Nasdaq listing stays central
I-Mab is identified as Nasdaq-listed under ticker NBP in the September 2026 analyst coverage. Its biotechnology profile spans biologic therapies for oncology and autoimmune or inflammatory diseases, making clinical progress and financing needs the two key valuation variables.
IMAB stock facts
- Company: I-Mab
- Ticker: NBP
- Primary exchange: Nasdaq
- Market capitalization: USD 186.2 million (as of September 15, 2026)
- 52-week range: USD 1.46-USD 6.79 (as of September 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
